Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prolymphocytic leukemia: the therapeutic strategy]

S Fava1, A De Paoli, E Grimi

  • 1Day-Hospital di Ematologia Oncologica e Oncologia Medica, Medicina 2a, Ospedale, Legnano.

Recenti Progressi in Medicina
|October 1, 1994
PubMed
Summary

Prolymphocytic leukemia (PLL) is an aggressive blood cancer. Combining splenic irradiation, chemotherapy, and leukapheresis offers the best treatment choice for improving patient prognosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030.

ESMO open·2024
Same author

Magnetic field expulsion in optically driven YBa<sub>2</sub>Cu<sub>3</sub>O<sub>6.48</sub>.

Nature·2024
Same author

NOD1 mediates interleukin-18 processing in epithelial cells responding to Helicobacter pylori infection in mice.

Nature communications·2023
Same author

Phase Diagram for Light-Induced Superconductivity in κ-(ET)_{2}-X.

Physical review letters·2021
Same author

Trends in thyroid function testing, neck ultrasound, thyroid fine needle aspiration, and thyroidectomies in North-eastern Italy.

Journal of endocrinological investigation·2021
Same author

Time-domain diffuse optics with 8.6  mm<sup>2</sup> fast-gated SiPM for extreme light harvesting.

Optics letters·2021

Area of Science:

  • Hematology
  • Oncology

Context:

  • Prolymphocytic leukemia (PLL) is a rare, aggressive lymphoproliferative malignancy.
  • It represents 5-10% of chronic lymphocytic leukemia (CLL) cases, typically affecting older males.
  • Patients often present with massive splenomegaly and a predominance of prolymphocytes.

Purpose:

  • To review the characteristics and treatment challenges of prolymphocytic leukemia.
  • To evaluate current therapeutic strategies and identify optimal treatment approaches.
  • To explore potential goals for transforming aggressive PLL into a milder clinical course.

Summary:

  • PLL is characterized by poor prognosis, with median survival of 3 years for B-PLL and 7 months for T-PLL.
  • Standard CLL therapies show limited efficacy (around 20% response rate) in PLL.

Related Experiment Videos

  • Combination therapy including splenic irradiation, anthracyclines, and leukapheresis is considered the best therapeutic choice.
  • Fludarabine demonstrates antileukemic activity, even in resistant cases.

    • Impact:

    • Highlights the limitations of current PLL treatments.
    • Suggests a multimodal therapeutic approach for improved outcomes.
    • Emphasizes the need for novel strategies to alter the aggressive clinical course and long-term prognosis of PLL.